INTRODUCTION: New Zealand (NZ) guidelines recommend treating people for cardiovascular disease (CVD) risk on the basis of five-year absolute risk using a NZ adaptation of the Framingham risk equation. A diabetes-specific Diabetes Cohort Study (DCS) CVD predictive risk model has been developed and validated using NZ Get Checked data.
Introduction
Globally there is an epidemic of Type 2 diabetes. 1, 2 It was estimated that in 2010 there were over 195 000 people in New Zealand (NZ) with diabetes-5.6% of the adult population. 3 People with diabetes are at increased risk of dying of cardiovascular disease (CVD) which accounts for almost 50% of all deaths amongst people with diabetes. 4, 5 There is considerable evidence that energetic management of risk factors such as blood pressure, dyslipidaemia, and glycaemia reduces the risk of CVD in people with diabetes. [6] [7] [8] [9] [10] [11] However, it is accepted that rather than treating risk factors separately, clinicians should use absolute CVD risk to guide patient management. 12, 13 NZ guidelines for cardiovascular risk assessment use a predictive risk equation adapted from J PRIM HEALTH CARE 2012;4(3):181-188.
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the United States Framingham Heart Study. 14, 15 This equation has a number of disadvantages for predicting risk of CVD amongst people with diabetes in NZ. In particular, the Framingham cohort was from the United States, did not include ethnic groups that are important in NZ, and only included a small number of people with diabetes. 16 In addition, the equation does not include a number of diabetes-specific variablessuch as duration of diabetes, glycaemic control, and albuminuria-that are predictive of cardiovascular outcomes. [17] [18] [19] [20] The NZ adaptation of the Framingham model does include adding a single additional five-year risk of 5% for these factors. 14 In 2010, Elley et al. reported two predictive CVD equations based on the New Zealand Diabetes Cohort Study (DCS). This was a prospective open cohort that used data from a national primary care diabetes programme (Diabetes Get Checked), which commenced in 2000. 21 Full details of the derivation and validation of the equation are described in the original article. 21 Briefly, data from 36 127 people with Type 2 diabetes, but without pre-existing CVD, were matched to national hospitalisation and mortality databases. Predictor variables for the first equation (DCS-A) included age at diagnosis, duration of diabetes, sex, ethnicity, smoking status, systolic blood pressure, HbA1c, total cholesterol: HDL cholesterol ratio (TC/HDL), and the presence of microor macroalbuminuria. A second equation (DCS-B) also included current antihypertensive treatment. The performance of both equations was tested on 10 030 individuals from a different geographic area in NZ with discrimination and calibration superior to the original Framingham equation. 21 Before using a prognostic model in clinical practice it is important to validate it using data from other independent populations of patients. 22 This study aimed to validate the DCS models using data from a cohort of people routinely assessed in NZ general practice with PREDICT, a CVD risk assessment and management programme.
Methods
Design
This validation study uses data from primary care to assess the discrimination, calibration and reclassification implications of the DCS equations in predicting CVD events, compared with actual events over five years.
Study population
PREDICT is a web-based, real-time decision support programme that has been integrated with most practice management software in use in NZ primary care. 23 General practitioners and practice nurses enter required clinical data to create a risk profile. This profile is sent by a secure internet connection to a central server that returns the patient's NZ Framingham five-year cardiovascular risk score with management recommendations. At the same time, an electronic profile is stored and linked to an encrypted National Health Index (NHI) number. These were anonymously linked to national hospitalisation, pharmaceutical dispensing and mortality outcomes and also to regional laboratory data.
Individuals identified as having Type 2 diabetes and no known pre-existing CVD with a PRE-DICT assessment between 27 August 2002 and 31 December 2005 were included. Individuals were said to have diabetes if they were identified by their primary care physician as having diabetes at first risk assessment, or if they had been identified as having diabetes in the national hospitalisation database, or had been prescribed insulin or an oral hypoglycaemic agent prior to or on their first PREDICT assessment date. If the type of diabetes was unclear, we assigned them as Type 2 if they were never on insulin, if they had been on an oral hypoglycaemic agent, or if their age of onset was over 30 years in Maori and Pacific or over 50 in other ethnic groups. Preexisting CVD was identified from the primary care physician's risk assessment record.
Risk variables
Risk factor variables required for the DCS equations were extracted for each individual. Data on some of the variables were missing from early PREDICT risk assessments. Duration of diabetes was included if it could be calculated from any subsequent PREDICT risk assessment record. Missing laboratory data were obtained from laboratory records where results from up to five years prior to the baseline assessment or two weeks after the assessment were available. After the addition of these data, only individuals with a complete minimum dataset were included in the final study cohort. Ethnicity was derived from both the primary care practitioner records and the encrypted NHI database and was prioritised in the order: Maori, Pacific, South Asian, East Asian, 'Other' and European.
WHAT GAP THIS FILLS
Outcome measures
Primary care data were linked to national hospitalisation and mortality databases by NHI number to identify all CVD events over the five years following baseline for each individual. CVD events included hospital admission or death from ischaemic heart disease, cerebrovascular disease or peripheral vascular disease. These were identified from national hospital and mortality databases coded according to ICD-9 and ICD-10 (see the appendix in the web version of this paper). 21 Five-year risk was calculated for each individual according to both the NZ Framingham and the DCS equations. 21 
Analyses
We compared predicted risk with observed outcomes. To assess discrimination, the ability of the models to distinguish between individuals who do or do not have a subsequent CVD event, we calculated the area under the receiver operating characteristic (ROC) curve (C statistic). 13, 22, 24 Calibration was assessed by comparing the observed and predicted probabilities of CVD events in the pre-specified deciles of DCS model risk, and performing a Hosmer-Lemeshow test for equivalence. The effect of reclassification of risk from the NZ Framingham model to the DCS models was measured using a 15% five-year cardiovascular risk threshold. NZ guidelines recommend drug treatment with five-year risks above 15%. A scatter plot of risks predicted by the two models with these pre-determined risk categories was also produced. 24 All analyses were undertaken using Stata ® 11.2.
Ethical approval
This validation study was approved by the Multiregion Ethics Committee (WGT/04/09/077) as part of the Diabetes Cohort Study. The PRE-DICT cohort study and research process was ap- 
Results
Study population
The derivation of the study cohort and subsequent CVD events is shown in Figure 1 . We classified 3044 (13.3%) people on the database as people with Type 2 diabetes without pre-existing CVD. Of these, 1829 (60.1%) had the minimum dataset of risk variables required and formed the final cohort for the study. About two-thirds of these individuals (65.9%) were included after having data added from sources other than the first risk assessment record. These data were diabetesspecific variables (HbA1c, urinary albumin/creatinine ratio, diabetes duration, and age of onset of diabetes). All individuals were followed for five years from their initial CVD risk assessment. During that time, 235 had first CVD events (12.8%), in which 45 (2.5%) were fatal and 190 (10.4%) were non-fatal events.
Baseline characteristics of participants are presented and compared with those of the 1215 people excluded due to missing variables in Table 1 . Compared with those included, a higher proportion of the excluded group were European and a lower proportion Pacific. Excluded participants had slightly higher systolic blood pressures and TC/HDL ratios and were less likely to be recorded as being past smokers. Although the two groups had similar risks of CVD events 
Reclassification
The effect of reclassification of risk from the NZ Framingham model to the DCS models was measured using a 15% five-year cardiovascular risk threshold. 
Discussion
Main finding
For this cohort of people with Type 2 diabetes, the DCS equations were better at discriminating risk of a first CVD event than the NZ Framingham equation currently being used in primary 
. Receiver operating curves for the DCS-B equation and the NZ Framingham CVD equation (five-year risk) Figure 3. Five-year risks observed in the study cohort compared with those predicted by the DCS-B equation and the NZ Framingham equation for different deciles of risk
care in NZ. The latter model in this cohort had an area under the ROC curve of 0.65 while the DCS equation gave an area of 0.68.
Strengths and limitations
The use of diabetes duration, HbA1c levels, and degrees of albuminuria are likely to contribute to better discrimination, particularly for higher risk groups. In addition, the DCS equation was developed in a cohort of much greater relevance to the NZ diabetes population than the Framingham equation, even though adjustments were made by the NZ guidelines.
14 There are a number of important methodological limitations in this validation study. One is that these equations were developed and validated on a cohort of people who may have being treated for their CVD risk. Indeed, the PREDICT programme, from which this cohort is gathered, is specifically intended to lower risk of CVD events by encouraging appropriate treatment. Historically, these equations have been used to predict the outcomes for patients if they were not treated. It is therefore likely that the risk of CVD events in this scenario would be higher than the observed risk in this cohort.
All three equations overestimated risk when compared to actual events in the cohort. This was in contrast to the initial validation study, where the DCS equations underestimated risk of first CVD event. 21 The first possibility is the effectiveness of the PREDICT programme in reducing risk, as discussed above. A second possibility is that the PREDICT cohort is at lower risk than the original DCS cohort, possibly because people with higher risk and comorbidities were enrolled earlier into the Get Checked programme. It is also possible that the difference is due to random error due to the relatively small number of observed events in this study. The overall five-year CVD incidence estimation is somewhat imprecise (12.8%, 95% CI 11.3-14.4%).
A further limitation is that an equation should ideally be validated on a population that is representative of the population on which it will eventually be used. It is a strength of this study that the PREDICT cohort is much more repre- sentative of NZ people with diabetes than the original Framingham equation cohort. Nevertheless, the baseline characteristics table suggested that this cohort was not completely representative of NZ people with diabetes. For example, Pacific people were over-represented compared to the overall diabetes population. It is also possible that our inability to obtain data on all patients in the original cohort has introduced a selection bias to our final validation cohort. As discussed, included subjects may have been at a slightly lower risk than those excluded. However, it is important that equations discriminate across diverse as well as representative populations.
Figure 4. Scatter plot of five-year risk of CVD events predicted by the DCS-B equation against the NZ Framingham equation with 15% five-year risk cut-offs shown
In validating any equation, it is important to have accurate data on the cohort being studied. The PREDICT data are collected by primary care physicians in routine care rather than by researchers and therefore may contain some inaccuracies.
As previously mentioned, some data were not available from the baseline risk assessment and had to be obtained from either laboratory data or subsequent risk assessment records. It is possible that other data, such as smoking status or diabetes duration, may be inaccurately recorded. Such deficiencies would lead to poorer discrimination of the equations. The degree to which they might also lead to systematic under-or overestimation of the predicted risks is more difficult to judge. However, these limitations also reflect the 'real-life' clinical situation in which these tools are used.
Implications for clinical practice
Whilst the current NZ guidelines for managing cardiovascular risk provide guidance for management across a broad range of risks, an important decision point is when to begin treatment of risk with medications.
14 At a population level, changing from the current NZ Framingham equation to one of the DCS equations would have a substantial impact on the way diabetes is managed in NZ. If this cohort were representative of people with diabetes in NZ, then changing to the DCS-B equation would result in recommending treating 53% of people with diabetes with lipidlowering and antihypertensive medication instead of 49%. Using the Ministry of Health estimates of the number of people with Type 2 diabetes in NZ, and excluding the estimated 22% of people QUANTITATIVE RESEARCH with diabetes who have pre-existing CVD, then 6503 extra people should be offered treatment. However, the benefit would be that an additional 2587 people, who would have had a first CVD event over the next five years, would be correctly identified and offered preventive therapy. As researchers interested in the population manage-ment of diabetes, we believe this would be a very worthwhile trade-off.
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At an individual level, the person with diabetes or their clinician needs to know, firstly, that on average over a five-year period, 13 people out of 100 will have a CVD event. Secondly, of these 13 people, the DCS equation will correctly identify 10 of these people so they can be offered treatment, whereas the current NZ Framingham equation will successfully predict eight. However, to achieve this, 53 of the 100 people will need to take medication (or five more than currently would be the case). Since it is impractical to offer individual patients the choice of model, we believe it is important to consult both clinicians and patient representatives as to which model is preferable. Should the DCS equation be approved, then it can be seamlessly added to the PREDICT decision support engine and available at the point of care.
In conclusion, we have validated the previously developed DCS equations using a different cohort of people with diabetes from the PREDICT dataset and compared its performance with the currently used NZ Framingham equation. We have shown that it has advantages over the current equation at a technical and population health level. From a patient perspective, it will lead to an increased chance of treatment, but also the opportunity to prevent more first CVD events. 
